NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure Ltd. (NASDAQ: NVCR ) shares rose in Friday’s premarket session before dropping after the company raised its full-year 2026 revenue outlook and reported second-quarter earnings and sales above analyst expectations. The stock closed Thursday at $19.99, up 28.39%. • NovoCure stock is among today’s weakest perform